Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV
This is a sources sought notice to identify qualified small businesses capable of conducting a specific pharmacoepidemiological data analysis project for the National Institute on Drug Abuse. The work involves using Veterans Affairs data to study the effects of certain medications on HIV and substance use disorder outcomes. The period of performance is 12 months from award with three 12-month option periods. The data for the project is housed at the VA Connect Medical Center in West Haven, CT. Capable vendors must demonstrate direct access to the required datasets and an already built analysis pipeline.